<DOC>
	<DOCNO>NCT00988117</DOCNO>
	<brief_summary>This open-label study investigate effect rivastigmine patch attention behavior Parkinson 's disease associate memory and/or think problem . Rivastigmine ( also sell name Exelon ) FDA approve medication use treatment mild moderate Alzheimer 's Disease ( AD ) memory think problem due Parkinson 's disease . Recently rivastigmine patch develop , show similar effectiveness few side effect increase caregiver preference compare capsule . This open-label 12 week study 15 subject diagnose Parkinson 's Disease mild moderate memory and/or think complaint treat rivastigmine patch UCSF . This study also analyze mechanism rivastigmine patch work people Parkinson 's disease memory and/or think problem .</brief_summary>
	<brief_title>The Effects Rivastigmine Patch Parkinson 's Disease With Memory and/or Thinking Problems</brief_title>
	<detailed_description>Participation study require four visit : screen visit ensure eligibility , initial/baseline visit medication distribute dosage lower optimal recommended dosage , four week follow-up visit dosage medication increase optimal amount , final twelve week follow visit . - In screen visit patient undergo neurological exam ( include review medical history short physical exam ) , electrocardiogram ( painless procedure measure electrical activity heart ) , cognitive testing ( memory think test ) , blood draw . - At Baseline/Initial visit patient receive brief physical exam , additional cognitive testing , MRI scan . Afterwards , study drug distribute . - At four week follow visit patient ask abbreviated cognitive neurological test study drug re-distributed target dosage . - At final twelve week visit patient receive additional cognitive neurological testing , MRI scan . - Study compliance adverse event review every two week throughout study , whether person phone .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Dementia</mesh_term>
	<mesh_term>Rivastigmine</mesh_term>
	<criteria>Must meet research criterion Parkinson 's Disease Dementia ( PDD ) Males female , age 55 100 Able undergo psychometric test MiniMental State Examination â‰¥ 21 Clinical Dementia Rating &lt; 2 Reliable informant frequent contact patient NonEnglish speaking , cognitive test English Evidence neurological psychiatric disorder preclude diagnosis PDD ( include , limited , stroke , psychotic disorder , severe bipolar unipolar depression , seizure disorder , head injury loss consciousness ) within past year Concurrent treatment acetylcholinesterase inhibitor ( include rivastigmine pill patch form ) , antipsychotic agent ( exclude quetiapine dosages 150 mg low , abilify geodon medication commonly use treatment Parkinson 's Disease ( PD ) psychosis affect result study ) , mood stabilizer ( valproate lithium ) benzodiazepine ( temazepam zolpidem ) Positive urine drug screen suspect alcohol substance abuse within last 1 year Current malignancy , clinically significant hematological , endocrine , cardiovascular , renal , hepatic , gastrointestinal neurological disease . If condition stable least past year judge investigator interfere patient 's participation study , patient may include Systolic blood pressure 180 less 90 mm Hg . Diastolic blood pressure great 105 less 50 mm Hg ECG abnormal judge clinically significant investigator Use investigational drug participation investigational drug study within 30 day screen Geriatric Depression Score score &gt; 15/30 Hachinski score &gt; 4</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>PDD</keyword>
	<keyword>Parkinson 's Disease Dementia</keyword>
	<keyword>rivastigmine</keyword>
	<keyword>rivastigmine patch</keyword>
	<keyword>open label</keyword>
	<keyword>Parkinson 's Disease</keyword>
	<keyword>Parkinsons Disease</keyword>
	<keyword>memory</keyword>
	<keyword>Exelon</keyword>
	<keyword>Exelon Patch</keyword>
</DOC>